367217312018-01-012018-12-31367217312018-01-012018-12-31Direktionsmedlem 01367217312017-12-31367217312018-12-31367217312017-01-012017-12-31367217312018-01-012018-12-31fsa:RetainedEarningsMember367217312017-01-012017-12-31fsa:RetainedEarningsMember367217312017-01-012017-12-31fsa:ProposedDividendRecognisedInEquityMember367217312018-01-012018-12-31fsa:RetainedEarningsMember367217312017-01-012017-12-31fsa:RetainedEarningsMember367217312018-12-31fsa:ContributedCapitalMember367217312017-12-31fsa:ContributedCapitalMember367217312018-12-31fsa:RetainedEarningsMember367217312017-12-31fsa:RetainedEarningsMember367217312018-12-31Kapitalklasse 01367217312018-12-31fsa:TaxLossesMember367217312017-12-31fsa:TaxLossesMember367217312018-01-012018-12-31fsa:ContributedCapitalMember367217312018-01-012018-12-31Revisionsvirksomhed 01367217312018-01-012018-12-31Revisionsvirksomhed 01 - Revisor 01iso4217:DKKpuresharesThe Company’s purpose is to do business with articles on health care and according to the Executive Borad’s discretion in business related thereto.The Company’s loss is DKK 189k, which isn’t satisfying. The primary reason to the loss, are the development in the USD exchange rate, high marketing and administrative costs. No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.Imad Mousa Kadhim Al-MousaExecutive Board have today considered and approved the annual report of UR Medicine for Medical Supplies & Laboratories ApS for the financial year 01.01.2018 - 31.12.2018.The annual report is presented in accordance with the Danish Financial Statements Act. I recommend the annual report for adoption at the Annual General Meeting. I believe that the management commentary contains a fair review of the affairs and conditions referred to therein. 493427713842733700470591151785919754248642606197542486426064934277128986134615064133913750530007374111310658991147766967431017762153500035000996039648652968-201933-380355-201933-380355-241581-1023363Inventories are measured at the lower of cost using the FIFO method and net realisable value. The net realisable value of inventories is calculated as the estimated selling price less completion costs and costs incurred to execute sale. Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts. Deferred tax is recognised on all temporary differences between the carrying amount and the tax-based value of assets and liabilities, for which the tax-based value is calculated based on the planned use of each asset. Deferred tax assets, including the tax base of tax loss carryforwards, are recognised in the balance sheet at their estimated realisable value, either as a set-off against deferred tax liabilities or as net tax assets.Current joint taxation contributions payable or joint taxation contributions receivable are recognised in the balance sheet, calculated as tax computed on the taxable income for the year, which has been adjusted for prepaid tax. For tax losses, joint taxation contributions receivable are only recognised if such losses are expected to be used under the joint taxation arrangement. Cash comprises cash in hand and bank deposits. Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value. Revenue from the sale of services is recognised in the income statement when delivery is made to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed. Other external expenses include expenses relating to the Entity’s ordinary activities, including expenses for premises, stationery and office supplies, administrative costs, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets. Cost of sales comprises goods consumed in the financial year measured at cost, adjusted for ordinary inventory writedowns.Other financial income comprises dividends etc received on other investments, interest income, including interest income on receivables from group enterprises, net capital gains on securities, payables and transactions in foreign currencies, amortisation of financial assets as well as tax relief under the Danish Tax Prepayment Scheme etc. Other external expenses include expenses relating to the Entity’s ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etcTax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity. 9960324504753963110571356024051919-5300000737436721731UR Medicine for Medical Supplies & Laboratories ApSKolding2019-06-25 Imad Mouse Kadhim Al-Mousa In my opinion, the financial statements give a true and fair view of the Entity’s financial position at 31.12.2018 and of the results of its operations for the financial year 01.01.2018 - 31.12.2018.2019-06-25KoldingGross profit or loss comprises revenue, other operating income and external expenses. 33963556Deloitte Statsautoriseret RevisionspartnerselskabDokken Postbox 2006701 Esbjerg19754248642606186411420526955000050000181411420026951113106589911-188581-798223-53000-225140-188581-798223-188581-798223-188581-798223500005000018141142002695Ordinary shares50530000530000ÅrsrapportRegnskabsklasse BEsbjerg2019-06-2550000Haderslevvej1406000KoldingDokkenPostbox 20086701EsbjergTo the shareholders of UR Medicine for Medical Supplies & Laboratories ApSManagement is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, Management is responsible for assessing the Entity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless Management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.Our responsibility is to express a conclusion on the financial statements. This requires that we plan and perform procedures to obtain limited assurance about our conclusion on the financial statements and that we also perform specifically required supplementary procedures for the purpose of obtaining additional assurance about our conclusion. An extended review consists of making inquiries, primarily of management and, if appropriate, of other entity personnel, performing analytical and the specifically required supplementary procedures as well as evaluating the evidence obtained. The procedures performed in an extended review are less in scope than in an audit, and accordingly we do not express an audit opinion on the financial statements.We conducted our extended review in accordance with the assurance engagement standard for small enterprises as issued by the Danish Business Authority and the standard on extended review of financial statements prepared in accordance with the Danish Financial Statements Act as issued by FSR - Danish Auditors. Our responsibilities under those standards and requirements are further described in the ”Auditor’s responsibilities for the extended review of the financial statements”. We are independent of the Entity in accordance with the International Ethics Standards Board for Accountants’ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our conclusion.We have performed an extended review of the financial statements of UR Medicine for Medical Supplies & Laboratories ApS for the financial year 01.01.2018 - 31.12.2018, which comprise the income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act. Based on our extended review, in our opinion, the financial statements give a true and fair view of the Entity’s financial position at 31.12.2018 and of the results of its operations for the financial year 01.01.2018 - 31.12.2018 in accordance with the Danish Financial Statements Act.Management is responsible for the management commentary. Our opinion on the financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon. In connection with our extended review of the financial statements our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the extended review or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act.Based on the work we have performed, we conclude that the management commentary is in accordance with financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.505000020002000Erklæring om udvidet gennemgang225140-188581-798223The accounting policies applied to these financial statements are consistent with those applied last year. State Authorised Public AccountantAnders Rasmussen79 12 84 442018-01-012018-12-312017-12-312017-01-01mne34316-22514010005000033963556Deloitte Statsautoriseret Revisionspartnerselskab